Profusa Secures Lumee™ Oxygen Platform Distributor in Spain

Rhea-AI Summary

Profusa (NASDAQ: PFSA), a digital health company, has signed a Letter of Intent (LOI) for a distribution agreement with Dismeval, S.L. to market its Lumee Oxygen platform in Spain, including the Canary and Balearic Islands.

The partnership marks Profusa's first step in building its European distribution infrastructure. The company targets a $10.5B+ global addressable market for its tissue oxygen technology across three key indications: peripheral artery disease, chronic wounds, and critical limb ischemia. The European market presents significant potential with over 300,000 endovascular procedures annually.

Positive

• Expansion into European market through Spanish distribution agreement
• Large addressable market of $10.5B+ globally
• Access to over 300,000 annual endovascular procedures in Europe
• Partnership with experienced medical device distributor with regional expertise

Negative

• None.

BERKELEY, Calif, July 31, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces it has signed a Letter of Intent (LOI) to enter into a distribution agreement in Spain for its Lumee Oxygen platform. The Spanish distributor, Dismeval, S.L., specializes in the distribution of medical and surgical equipment throughout Spain, including the Canary and Balearic Islands. The distribution partner has an experienced and well trained team with in-depth knowledge of the medical device sector and hands-on expertise in supporting hospital-based clinical and technical operations.

"Establishing a distributor partner in Spain for our Lumee Oxygen platform is the first, tangible step as we build a robust distribution infrastructure in Europe, in line with our strategy to bring our pioneering real-time personal healthcare technologies to the clinical community, driving growth in our business,” said Ben Hwang, Ph.D., Profusa’s Chairman and CEO. “We estimate a $10.5B+ global addressable market for our tissue oxygen technology across three indications – peripheral artery disease, chronic wounds, and critical limb ischemia. In Europe, the clinical need comes to over 300,000 endovascular procedures a year. We look forward to bringing our differentiated, next generation biosensor technology to address this market need.”

About Profusa
Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.

“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.

For more information, visit https://profusa.com.

Special Note Regarding Forward-Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa or the combined company. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including risks regarding the highly volatile nature of the price of Bitcoin and other cryptocurrencies, as well as the risk that the Company's stock price may be highly correlated to the price of the digital assets that it holds. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and described in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.

Contacts
Investor and Media Contacts
email: info@coreir.com
phone: 1 (212) 655-0924

FAQ

What distribution agreement did Profusa (NASDAQ: PFSA) announce in July 2025?

Profusa signed a Letter of Intent (LOI) with Dismeval, S.L. to distribute its Lumee Oxygen platform throughout Spain, including the Canary and Balearic Islands.

What is the market size for Profusa's tissue oxygen technology?

Profusa estimates a $10.5B+ global addressable market across three indications: peripheral artery disease, chronic wounds, and critical limb ischemia.

How many endovascular procedures are performed annually in Europe according to Profusa?

According to Profusa, there are over 300,000 endovascular procedures performed annually in Europe.

Which medical conditions does Profusa's Lumee Oxygen platform target?

The Lumee Oxygen platform targets three main conditions: peripheral artery disease, chronic wounds, and critical limb ischemia.

Who is Dismeval, S.L. and what is their role in Profusa's expansion?

Dismeval, S.L. is a Spanish distributor specializing in medical and surgical equipment distribution throughout Spain. They will serve as Profusa's distribution partner for the Lumee Oxygen platform with their experienced team and expertise in hospital-based operations.